HSP90 INHIBITORS POTENTIALLY OVERCOME CHEMORADIOTHERAPY RESISTANCE ASSOCIATED WITH HER2 AND NFfEB OVEREXPRESSION IN MIBC

被引：0
|
作者：
Yoshida, Soichiro
Koga, Fumitaka
Tatokoro, Manabu
Kawakami, Satoru
Fujii, Yasuhisa
Kumagai, Jiro
Neckers, Len
Kihara, Kazunori
机构：
来源：
JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期
关键词：
D O I：
10.1016/j.juro.2011.02.1091
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1054
引用
收藏
页码：E424 / E424
页数：1
相关论文
共 50 条
  • [31] Cell surface hsp90 interacts with the extracellular domain of her2 and contributes to receptor activation
    Sidera, K.
    Gaitanou, M.
    Matsas, R.
    Patsavoudi, E.
    FEBS JOURNAL, 2006, 273 : 95 - 95
  • [32] Studying the functions of HSP90 inhibitor for overcoming the resistance of lapatinib in HER-2 overexpression breast cancer cell lines
    Bae, J.
    Shin, S.
    Park, K.
    Jung, S.
    Lee, H.
    Kim, H. Y.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S117 - S117
  • [33] Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu
    Yan, Yan-yan
    Zheng, Li-sheng
    Zhang, Xu
    Chen, Li-kun
    Singh, Satyakam
    Wang, Fang
    Zhang, Jian-ye
    Liang, Yong-ju
    Dai, Chun-ling
    Gu, Lian-quan
    Zeng, Mu-sheng
    Talele, Tanaji T.
    Chen, Zhe-sheng
    Fu, Li-wu
    MOLECULAR PHARMACEUTICS, 2011, 8 (05) : 1687 - 1697
  • [34] Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda, Leticia
    Cortes, Javier
    BREAST, 2012, 21 (04): : 604 - 607
  • [35] Dual-targeted Drug Design of HER2 and HSP90 by CoMFA Model and Pharmacophore Analysis
    Huang, Hung-Jin
    Bau, Da-Tian
    Tsai, Ming-Hsui
    Hsu, Yuan-Man
    Ho, Tin-Yun
    Chen, Chien-Yu
    Chang, Yea-Huey
    Tsai, Fuu-Jen
    Tsai, Chang-Hai
    Chen, Calvin Yu-Chian
    PROCEEDINGS OF THE 2009 2ND INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND INFORMATICS, VOLS 1-4, 2009, : 837 - +
  • [36] Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90
    Chen Tian-wen
    Liang Ya-nan
    Feng Duo
    Tao Lin-yu
    Qi Ke
    Zhang Hao-yun
    Wang Hong-xian
    Lin Qiu-sheng
    Kong Heng
    JOURNAL OF BUON, 2013, 18 (01): : 51 - 56
  • [37] The Achilles heel of ErbB-2/HER2 - Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention
    Citri, A
    Kochupurakkal, BS
    Yarden, Y
    CELL CYCLE, 2004, 3 (01) : 51 - 60
  • [38] TARGETING MEK/ERK AND PI3K/AKT TO OVERCOME RESISTANCE OF HUMAN COLON CANCER TO HSP90 INHIBITORS
    Wang, Chun Yan
    Jiang, Chen Chen
    Guo, Su Tang
    Croft, Amanda
    Jin, Lei
    Tseng, Hsin-Yi
    Wang, Jia Yu
    Yan, Xu Guang
    Farrelly, Margaret
    Zhang, Xu Dong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 5 - 5
  • [39] Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
    Azimi, Alireza
    Caramuta, Stefano
    Seashore-Ludlow, Brinton
    Bostrom, Johan
    Robinson, Jonathan L.
    Edfors, Fredrik
    Tuominen, Rainer
    Kemper, Kristel
    Krijgsman, Oscar
    Peeper, Daniel S.
    Nielsen, Jens
    Hansson, Johan
    Brage, Suzanne Egyhazi
    Altun, Mikael
    Uhlen, Mathias
    Maddalo, Gianluca
    MOLECULAR SYSTEMS BIOLOGY, 2018, 14 (03)
  • [40] SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer.
    Chandarlapaty, S.
    Ye, Q.
    Huang, K.
    Fadden, P.
    Rosen, N.
    Solit, D.
    EJC SUPPLEMENTS, 2006, 4 (12): : 165 - 165
12345